Humacyte, Inc. Common Stock HUMA

Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.

• Zacks Investment Research 1 oct

  Humacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to Note

  Humacyte, Inc. (HUMA) stock declined 2.86% to $0.50, underperforming broader market gains. The stock has lost 13.23% over the past month. While the company expects EPS to improve 35.71% next quarter with revenue up 14.67%, full-year projections show earnings declining 53.85% despite revenue doubling. The stock holds a Zacks Rank #4 (Sell) rating, and its industry ranks in the bottom 27% of all sectors.

  

• GlobeNewswire Inc. 14 jul

  Humacyte Appoints Key Nephrologists as Advisors to Prepare for Planned Commercialization of the ATEV in Dialysis Access

  Humacyte, Inc. announced the appointment of two prominent nephrologists, Dr. Robert J. Kossmann and Dr. Prabir Roy-Chaudhury, as advisors to support the commercialization of its acellular tissue engineered vessel (ATEV) for hemodialysis access. The appointments follow positive Phase 3 V012 study results in women and plans to file a supplemental Biologic License Application with the FDA.

  

• Benzinga 10 jun

  Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

  Humacyte (NASDAQ: HUMA), a commercial-stage biotechnology company, announced the pricing of an underwritten public offering of approximately 47.6 million shares at $1.05 per share, generating $50 million in gross proceeds. The company plans to use the funds to commercialize Symvess®, file a Biologics License Application supplement for hemodialysis indication, and develop pipeline candidates. The offering is expected to close on June 12, 2026.

  

• GlobeNewswire Inc. 10 jun

  Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

  Humacyte, Inc. (Nasdaq: HUMA) announced the pricing of an underwritten public offering of approximately 47.6 million shares at $1.05 per share, expected to raise $50 million in gross proceeds. The company plans to use the net proceeds to fund commercialization of Symvess®, advance pipeline development, and support general corporate purposes. The offering is expected to close on or about June 12, 2026.

  

• GlobeNewswire Inc. 10 jun

  Humacyte, Inc. Announces Proposed Public Offering of Common Stock

  Humacyte, Inc. (Nasdaq: HUMA) announced an underwritten public offering of common stock with Barclays, BTIG, and Titan Partners as joint book-running managers. The company plans to use net proceeds to fund commercialization of Symvess®, file a supplemental BLA for hemodialysis indication, develop pipeline candidates, and support general corporate purposes.